WCN26-2839 LONG-TERM EFFICACY AND SAFETY OF PERIODIC REPEATED RITUXIMAB ADMINISTRATIONS FOR PEDIATRIC REFRACTORY NEPHROTIC SYNDROME: A MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY

Read full text Summarise with VIRAT
Authors: Ryosuke Yokokawa, Takayuki Okamoto, Toshiyuki Takahashi, Ryota Suzuki, Asahi Yamamoto, Asako Hayashi, Yasuyuki Sato, Atsushi Manabe
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Rituximab (RTX) is effective in preventing relapse in children with refractory nephrotic syndrome (NS), however most patients eventually relapse after RTX administration. Therefore, repeated RTX administrations and/or additional immunosuppressive therapies are often required, although a standardized RTX protocol has not yet been established. Adverse events such as late-onset agranulocytosis and hypogammaglobulinemia have also been reported, and the long-term safety of RTX therapy remains uncertain.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Vasculitis and related conditions Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105592–105592
Publication date
25 March 2026
Language
EN